Lasers in Medical Science

, Volume 11, Issue 1, pp 31–36 | Cite as

Photochemically-induced tissue injury observed very shortly after sensitizer injection

  • L. Bourletias
  • P. Lenz
  • J. Margonari
Original Articles
  • 23 Downloads

Abstract

In clinical photochemotherapy, irradiation is delayed by a few days with respect to sensitizer injection in order to enhance the specificity of action. However, there are animal experiments which, above all, require a strong response; this is expected to occur if the delay time is much shorter. To assess the influence of the delay time, lesions were produced in rat ears using haematoporphyrin derivative and green light, and characterized by a scoring system. It was found that, starting from the shortest experimentally accessible value (8 min), the intensity of lesions decreases with increasing delay time (by a factor of 2 in 90 min). This result suggests that the lesions are induced by circulating sensitizer. Dose fractionation, performed 97 min after injection, enhances the response (p<0.005).

Key words

Haematoporphyrin derivative In vivo Light fractionation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Svanberg K, Kjellen E, Ankerst J et al. Fluorescence studies of hematoporphyrin derivative in normal and malignant rat tissue.Cancer Res 1986,46:3803–8PubMedGoogle Scholar
  2. 2.
    Baumgartner R, Fuchs N, Jocham D et al. Pharmacokinetics of fluorescent polyporphyrin photofrin II in normal rat tissue and rat bladder tumor.Photochem Photobiol 1992,55:569–74PubMedGoogle Scholar
  3. 3.
    Kennedy JC, Nadeau P, Petryka ZJ et al. Clearance times of porphyrin derivatives from mice as measured by in vivo fluorescence spectroscopy.Photochem Photobiol 1992,55:729–34PubMedGoogle Scholar
  4. 4.
    Eckhauser ML, Persky J, Bonaminio A et al. Biodistribution of the photosensitizer dihaematoporphyrin ether.Lasers Med Sci 1986,2:101–6Google Scholar
  5. 5.
    Paramsothy M, Zainuddin J, Low KS. In vivo nuclear imaging studies of uptake and retention of Tc-99mlabelled HpD in a murine tumour.Lasers Med Sci 1989,4:205–10Google Scholar
  6. 6.
    Gomer CJ, Ferrario A. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.Cancer Res 1990,50:3985–90PubMedGoogle Scholar
  7. 7.
    Gomer CJ, Dougherty TJ. Determination of 3H- and 14C hematoporphyrin derivative distribution in malignant and normal tissue.Cancer Res 1979,39:146–51PubMedGoogle Scholar
  8. 8.
    Jori G, Tomio L, Reddi E et al. Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumor-bearing rats.Br J Cancer 1983,48:307–9PubMedGoogle Scholar
  9. 9.
    Wilson BC, Firnau G, Jeeves WP et al. Chromatographic analysis and tissue distribution of radiocopperlabelled haematoporphyrin derivatives.Lasers Med Sci 1988,3:71–80Google Scholar
  10. 10.
    Bellnier DA, Ho YK, Pandey RK et al. Distribution and elimination of photofrin II in mice.Photochem Photobiol 1989,50:221–8PubMedGoogle Scholar
  11. 11.
    Tromberg BJ, Orenstein A, Kimel S et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy.Photochem Photobiol 1990,52:375–85PubMedGoogle Scholar
  12. 12.
    Henderson BW, Dougherty TJ. How does photodynamic therapy work?Photochem Photobiol 1992,55:145–57PubMedGoogle Scholar
  13. 13.
    Ris HB, Altermatt HJ, Nachbur B et al. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxy-phenylchlorin in malignant mesothelioma.Int J Cancer 1993,53:141–6PubMedGoogle Scholar
  14. 14.
    Bellnier DA, Dougherty TJ. The time course of cutaneous porphyrin photosensitization in the murine ear.Photochem Photobiol 1989,49:369–72PubMedGoogle Scholar
  15. 15.
    Gibson SL, Van der Meid KR, Murant RS et al. Effects of various Photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas.Cancer Res 1990,50:7236–41PubMedGoogle Scholar
  16. 16.
    Foster TH, Murant RS, Bryant RG et al. Oxygen consumption and diffusion effects in photodynamic therapy.Radiat Res 1991,126:296–303PubMedGoogle Scholar
  17. 17.
    Foster TH, Hartley DF, Nichols MG, Hilf R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids.Cancer Res 1993,53:1249–54PubMedGoogle Scholar
  18. 18.
    Gomer CJ, Rucker N, Razum NJ, Murphree AL. In vitro and in vivo light dose rate effects related to hematoporphyrin derivative photodynamic therapy.Cancer Res 1985,45:1973–7PubMedGoogle Scholar
  19. 19.
    Graschew G, Shopova M, Anastassova G, Chakarova A. Light dose fractionation versus single-dose irradiation in photodynamic therapy of tumours.Lasers Med Sci 1988,3:173–7Google Scholar
  20. 20.
    Evensen JF, Moan J. Photodynamic therapy of C3H tumours in mice: Effect of drug/light dose fractionation and misonidazole.Lasers Med Sci 1987,3:1–6Google Scholar
  21. 21.
    Benstead K, Moore JV. The effect of fractionation of light treatment on necrosis and vascular function of normal skin following photodynamic therapy.Br J Cancer 1988,58:301–5PubMedGoogle Scholar
  22. 22.
    Boyle DG, Potter WR. Photobleaching of photofrin II as a means of eliminating skin photosensitivity.Photochem Photobiol 1987,46:997–1001PubMedGoogle Scholar
  23. 23.
    Anholt H, Moan J. Fractionated treatment of CaD2 tumors in mice sensitized with aluminium phthalocyanine tetrasulfonate.Cancer Lett 1992,61:263–7PubMedGoogle Scholar
  24. 24.
    Ma LW, Moan J, Peng Q. Effects of light exposure on the uptake of photofrin II in tumors and normal tissues.Int J Cancer 1992,52:120–3PubMedGoogle Scholar
  25. 25.
    van Gemert JC, Berenbaum MC, Gijsbers GHM. Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative.Br J Cancer 1985,52:43–9PubMedGoogle Scholar
  26. 26.
    Potter WR, Mang TS, Dougherty TJ. The theory of photodynamic therapy dosimetry: consequences of photodestruction of sensitizer.Photochem Photobiol 1987,46:97–101PubMedGoogle Scholar

Copyright information

© W.B. Saunders Company Ltd. 1996

Authors and Affiliations

  • L. Bourletias
    • 1
  • P. Lenz
    • 1
  • J. Margonari
    • 1
  1. 1.Institut National de la Santé et de la Recherche MédicaleLyonFrance

Personalised recommendations